HEPACAM2 Inhibitors
HEPACAM2 inhibitors refer to a group of chemical compounds specifically designed to attenuate the function of the HEPACAM2 protein, which is implicated in various cellular processes. The inhibition of HEPACAM2 can occur through a variety of mechanisms, each tailored to interact with the protein's unique structure or the signaling pathways it influences. For instance, certain inhibitors may directly bind to the active site of HEPACAM2, effectively blocking its interaction with binding partners or substrates. This direct blockade prevents the protein from performing its normal function, which could be crucial in processes such as cell adhesion, signal transduction, or cellular growth regulation. Other HEPACAM2 inhibitors might work allosterically, altering the protein's conformation and rendering it functionally inactive without competing for the active site. These allosteric inhibitors are particularly valuable as they can offer high specificity, reducing the likelihood of off-target effects that might arise from interactions with proteins of similar domains or active sites.
In addition to direct binding, HEPACAM2 inhibitors may also exert their effects by interfering with the regulatory mechanisms that control the expression and activity of HEPACAM2. Some inhibitors might impede the phosphorylation events that are necessary for HEPACAM2 activation, thereby keeping the protein in an inactive state. Other compounds could prevent the proper localization of HEPACAM2 within the cell, crucial for its function, by disrupting the cytoskeletal components or membrane domains it associates with. Furthermore, some HEPACAM2 inhibitors may act upstream, targeting signaling molecules or transcription factors that regulate the synthesis of HEPACAM2, hence reducing its overall levels and activity within the cell. Each inhibitor's mode of action is highly specific to the structural features and regulatory pathways associated with HEPACAM2, ensuring that inhibition is achieved through precise molecular interactions that mitigate the protein's activity without affecting the broader cellular landscape.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of phosphoinositide 3-kinases (PI3Ks). Since PI3K signaling is crucial for multiple cellular functions, LY294002's inhibition of PI3K can reduce Akt phosphorylation and activity, leading to a decrease in downstream signaling events that may involve HEPACAM2 in cellular adhesion processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK, which prevents the activation of MAPK/ERK pathway. As HEPACAM2 is involved in cell-cell adhesion, inhibition of MAPK/ERK signaling can alter cellular responses that depend on HEPACAM2's function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A pyridinyl imidazole compound that inhibits p38 MAP kinase. The inhibition of p38 MAP kinase can modify the cytoskeletal architecture and potentially reduce the functional role of HEPACAM2 in maintaining cell structure and adhesion. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A selective inhibitor of the Rho-associated protein kinase (ROCK). ROCK plays a role in regulating the actin cytoskeleton; therefore, Y-27632 can lead to changes in cell shape and motility, indirectly affecting HEPACAM2-mediated cell adhesion. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
A Rac1 inhibitor that disrupts Rac1 interaction with its guanine nucleotide exchange factors (GEFs). As Rac1 is involved in actin cytoskeleton organization, NSC23766 indirectly impacts cellular processes that may require HEPACAM2 for cell adhesion and signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An anthrapyrazolone inhibitor that selectively inhibits c-Jun N-terminal kinase (JNK). Inhibition of JNK signaling can lead to alterations in cellular adhesion and morphology, potentially affecting HEPACAM2's role in these processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A steroidal metabolite that acts as a potent PI3K inhibitor. By inhibiting PI3K, Wortmannin can affect various signaling pathways including those that regulate cell adhesion and migration where HEPACAM2 may play a role. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An inhibitor of MEK1/2, which blocks the MAPK/ERK pathway. Through the inhibition of this pathway, U0126 can indirectly interfere with the functional activity of HEPACAM2 in cell communication and adhesion. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $179.00 $307.00 $455.00 $924.00 $1689.00 | 7 | |
A selective inhibitor of myosin II ATPase activity. By inhibiting myosin II, Blebbistatin can affect cell contractility and adhesion, processes in which HEPACAM2 might be involved given its cellular localization. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
An inhibitor of myosin light chain kinase (MLCK), which is involved in the regulation of the actin cytoskeleton and cellular contraction. ML-7 thus could influence HEPACAM2's role in cell shape and adhesion dynamics. | ||||||